Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

R B Herberman¹, J Hiserodt¹, N Vujanovic¹, C Balch², E Lotzova², R Bolhuis³, S Golub⁴, L L Lanier⁵, J H Phillips⁵, C Riccardi⁶, J Ritz⁷, A Santoni⁸, R E Schmidt⁹, A Uchida¹⁰

Affiliations

¹ Pittsburgh Cancer Institute and Departments of Medicine and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
² Department of General Surgery, MD Anderson Hospital and Tumor Institute, Houston, TX 77030, USA.
³ Department of Immunology, Dr Daniel den Hoed Cancer Center, 3008 AE Rotherdam, The Netherlands.
⁴ Department of Surgery, Division of Oncology, UCLA School of Medicine, University of California, Los Angeles, CA 90024, USA.
⁵ Becton Dickinson Monoclonal Center, Mountain View, CA 94043, USA.
⁶ Institute of Pharmacology, University of Perugia, Perugia, Italy.
⁷ Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
⁸ Universita degli Stude 'Sapienze', Rome, Italy.
⁹ Departments of Medicine and Clinical Immunology, Medizinische Hochschule Hannover, D-3000 Hannover 61, Fed. Rep. Germany.
¹⁰ Department of Radiation System Biology, Radiation Biology Center, Kyoto University, Kyoto 606, Japan.

PMID: 25290217
DOI: 10.1016/0167-5699(87)90035-1

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

R B Herberman et al. Immunol Today. 1987.

. 1987;8(6):178-81.

doi: 10.1016/0167-5699(87)90035-1.

Authors

R B Herberman¹, J Hiserodt¹, N Vujanovic¹, C Balch², E Lotzova², R Bolhuis³, S Golub⁴, L L Lanier⁵, J H Phillips⁵, C Riccardi⁶, J Ritz⁷, A Santoni⁸, R E Schmidt⁹, A Uchida¹⁰

Affiliations

¹ Pittsburgh Cancer Institute and Departments of Medicine and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
² Department of General Surgery, MD Anderson Hospital and Tumor Institute, Houston, TX 77030, USA.
³ Department of Immunology, Dr Daniel den Hoed Cancer Center, 3008 AE Rotherdam, The Netherlands.
⁴ Department of Surgery, Division of Oncology, UCLA School of Medicine, University of California, Los Angeles, CA 90024, USA.
⁵ Becton Dickinson Monoclonal Center, Mountain View, CA 94043, USA.
⁶ Institute of Pharmacology, University of Perugia, Perugia, Italy.
⁷ Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
⁸ Universita degli Stude 'Sapienze', Rome, Italy.
⁹ Departments of Medicine and Clinical Immunology, Medizinische Hochschule Hannover, D-3000 Hannover 61, Fed. Rep. Germany.
¹⁰ Department of Radiation System Biology, Radiation Biology Center, Kyoto University, Kyoto 606, Japan.

PMID: 25290217
DOI: 10.1016/0167-5699(87)90035-1

Abstract

Leukocytes in blood and spleen can be activated by interleukin 2 (IL-2) to become cytotoxic to certain tumor cell lines in vitro. Recent evidence suggests that such lymphokine-activated killer (LAK) cells can bring about the regression of solid tumors in animals and patients, under certain circumstances. Here, Ronald Herberman and colleagues from eight international laboratories, review what is known of the characteristics of LAK cell activity and conclude that most of it can be attributed to natural killer cells stimulated by IL-2.

PubMed Disclaimer

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

Affiliations

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

Authors

Affiliations

Abstract

LinkOut - more resources

Full Text Sources